Antifungal therapy in a murine model of disseminated infection by Cryptococcus gattii

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 10, 2010, Pages 4074-4077

  Calvo, Enrique ^a   Pastor, F Javier ^a   Rodríguez, M Mar ^a   Pujol, Isabel ^b   Guarro, Josep ^a  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; POSACONAZOLE; VORICONAZOLE;

AGAR DIFFUSION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOASSAY; BRAIN TISSUE; CLINICAL EVALUATION; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; FUNGAL STRAIN; HUMAN; LUNG PARENCHYMA; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; SURVIVAL; TREATMENT OUTCOME;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; MALE; MICE; PYRIMIDINES; TRIAZOLES;

EID: 77957376507     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00172-10     Document Type: Article

References (30)

1. Barchiesi, F., A. M. Schimizzi, F. Caselli, D. Giannini, V. Camiletti, B. Fileni, A. Giacometti, L. F. Di Francesco, and G. Scalise. 2001. Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans. J. Antimicrob. Chemother. 48:769-773.
2. Bodasing, N., R. A. Seaton, G. S. Shankland, and D. Kennedy. 2004. Cryptococcus neoformans var. gattii meningitis in an HIV-positive patient: first observation in the United Kingdom. J. Infect. 49:253-255.
3. Bodet C. A., III, J. H. Jorgensen, and D. J. Drutz. 1985. Simplified bioassay method for measurement of flucytosine or ketoconazole. J. Clin. Microbiol. 22:157-160.
4. + T lymphocytes in host resistance against Cryptococcus neoformans in the central nervous system of immunized mice. Infect. Immun. 68:456-462.
5. Reference deleted.
6. Chen, Y. C., S. C. Chang, C. C. Shih, C. C. Hung, K. T. Luhbd, Y. S. Pan, and W. C. Hsieh. 2000. Clinical features and in vitro susceptibilities of the two varieties of Cryptococcus neoformans in Taiwan. Diagn. Microbiol. Infect. Dis. 36:175-183.
7. Christiansen, K. J., E. M. Bernard, J. W. Gold, and D. Armstrong. 1985. Distribution and activity of amphotericin B in humans. J. Infect. Dis. 152:1037-1043.
8. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility of yeasts. Approved standard M27-A3, 3rd ed. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Esposito, V., R. Viglietti, M. Gargiulo, R. Parrella, M. Onofrio, V. Sangiovanni, D. Ambrosino, and A. Chirianni. 2009. Successful treatment of cryptococcal meningitis with a combination of liposomal amphotericin B, flucytosine and posaconazole: two cases reports. In Vivo 23:465-468.
10. Fittler, A., B. Kocsis, I. Gerlinger, and L. Botz. 2010. Optimization of bioassay method for the quantitative microbiological determination of amphotericin B. Mycoses 53:57-61.
11. Friese, G., T. Discher, R. Füssle, A. Schmalreck, and J. Lohmeyer. 2001. Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease. AIDS 15:2344-2345. (Pubitemid 34059852)
12. Glück, T., B. Kiefmann, M. Grohmann, W. Falk, R. H. Straub, and J. Schölmerich. 2005. Immune status and risk for infection in patients receiving chronic immunosuppressive therapy. J. Rheumatol. 32:1473-1480. (Pubitemid 41113967)
13. Gómez-López, A., O. Zaragoza, M. Dos Anjos Martins, M. C. Melhem, J. L. Rodríguez-Tudela, and M. Cuenca-Estrella. 2008. In vitro susceptibility of Cryptococcus gattii clinical isolates. Clin. Microbiol. Infect. 14:727-730.
14. Hill, J. O., and P. L. Dunn. 1993. A T cell-independent protective host response against Cryptococcus neoformans expressed at the primary site of infection in the lung. Infect. Immun. 61:5302-5308.
15. Izumikawa, K., Y. Zhao, K. Motoshima, T. Takazono, T. Saijo, S. Kurihara, S. Nakamura, T. Miyazaki, M. Seki, H. Kakeya, Y. Yamamoto, K. Yanagihara, Y. Miyazaki, T. Hayashi, and S. Kohno. 2008. A case of pulmonary cryptococcosis followed by pleuritis in an apparently immunocompetent patient during fluconazole treatment. Med. Mycol. 46:596-599.
16. Lindenberg Ade, S., M. R. Chang, A. M. Paniago, Mdos S. Lázera, P. M. Moncada, G. F. Bonfim, S. A. Nogueira, and B. Wanke. 2008. Clinical and epidemiological features of 123 cases of cryptococcosis in Mato Grosso do Sul, Brazil. Rev. Inst. Med. Trop. Sao Paulo 50:75-78.
17. Litvintseva, A. P., R. Thakur, L. B. Reller, and T. G. Mitchell. 2005. Prevalence of clinical isolates of Cryptococcus gattii serotype C among patients with AIDS in sub-Saharan Africa. J. Infect. Dis. 192:888-892.
18. + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105:2862-2868.
19. Perfect, J. R., G. M. Cox, R. K. Dodge, and W. A. Schell. 1996. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob. Agents Chemother. 40:1910-1913.
20. Perfect, J. R., W. E. Dismukes, F. Dromer, D. L. Goldman, J. R. Graybill, R. J. Hamill, T. S. Harrison, R. A. Larsen, O. Lorthoraly, M. H. Nguyen, P. G. Pappas, W. G. Powderly, N. Singh, J. D. Sobel, and T. C. Sorrell. 2010. Practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin. Infect. Dis. 50:291-322.
21. Perfect, J. R., K. A. Marr, T. J. Walsh, R. N. Greenberg, B. DuPont, J. de la Torre-Cisneros, G. Just-Nübling, H. T. Schlamm, I. Lutsar, A. Espinel-Ingroff, and E. Johnson. 2003. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 36:1122-1131.
22. Pitisuttithum, P., R. Negroni, J. R. Graybill, B. Bustamante, P. Pappas, S. Chapman, R. S. Hare, and C. J. Hardalo. 2005. Activity of posaconazole in the treatment of central nervous system fungal infections. J. Antimicrob. Chemother. 56:745-755.
23. Saag, M. S., J. R. Graybill, R. A. Larsen, P. G. Pappas, J. R. Perfect, W. G. Powderly, J. D. Sobel, and W. E. Dismukes. 2000. Practice guidelines for the management of cryptococcal disease. Clin. Infect. Dis. 30:710-718.
24. Serena, C., F. J. Pastor, M. Mariné, M. Mar Rodríguez, and Josep Guarro. 2007. Efficacy of voriconazole in a murine model of cryptococcal central nervous system infection. J. Antimicrob. Chemother. 60:162-165.
25. Severo, L. C., F. de Mattos Oliveira, and A. T. Londero. 1999. Cryptococcosis due to Cryptococcus neoformans var. gattii in brazilian patients with AIDS. Report of three cases. Rev. Iberoam. Micol. 16:152-154.
26. Soares, B. M., D. A. Santos, L. M. Kohler, G. da Costa César, I. R. de Carvalho, M. dos Anjos Martins, and P. S. Cisalpino. 2008. Cerebral infection caused by Cryptococcus gattii: a case report and antifungal susceptibility testing. Rev. Iberoam. Micol. 31:242-245.
27. Sorrell, T. C. 2001. Cryptococcus neoformans variety gattii. Med. Mycol. 39:155-158.
28. Sugar, A. M., and X. Liu. 2001. Efficacy of voriconazole in treatment of murine pulmonary blastomycosis. Antimicrob. Agents Chemother. 45:601-604.
29. Thompson, G. R., III, N. P. Wiederhold, A. W. Fothergill, A. C. Vallor, B. L. Wickes, and T. F. Patterson. 2009. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob. Agents Chemother. 53:309-311.
30. + T cells in a protective immune response against Cryptococcus neoformans in the central nervous system. Med. Mycol. 44:1-11.